Cancer Therapy

License option agreement signed for cancer epitopes for ex vivo applications

Published in AIDS Weekly, November 18th, 2002

Epimmune, Inc., (NASDAQ:EPMN) a biotechnology company focused on the development of pharmaceutical products using multiple, specific epitopes to activate the body's immune system, announced that it had entered into an evaluation and license option agreement with Immuno-Designed Molecules, S.A. (IDM) for certain cancer antigens for use in IDM's ex vivo cancer therapy program.

Epimmune's cancer epitopes (antigen fragments) are derived from multiple tumor-associated antigens and contain both native and analog epitope sequences. IDM's technology consists of monocyte derived dendritic cells (dendritophages) loaded in vitro with tumor antigens or epitopes and then reinjected...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2002-11-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry